I am a biotechnology scientific leader and advisor with more than 30 years of experience in academic research, oncology, and therapeutic development. I help emerging companies evaluate target biology and therapeutic candidates, identify evidence gaps, and design experiments that guide development decisions.
My expertise includes preclinical pharmacology, translational strategy, GPCR biology, targeted protein degradation, biomarkers, and cell-based delivery. I advise on model selection, efficacy and mechanism-of-action studies, data interpretation, program prioritization, and CRO and academic collaborations.
I also support non-dilutive funding through scientific strategy, experimental planning, proposal writing, and review. At Cytonus, I helped secure more than $5 million in DoD, NIH, and CIRM funding. I connect rigorous science with practical development milestones and a clear funding rationale.
